Our vision is to achieve the extraordinary—delivering genetic medicines that transcend liver-based limitations, liberating patients from disease.
Liberate Bio Demonstrates First In Vivo CAR-M–Mediated B-Cell Depletion in Non-Human Primates
Read moreLiberate Bio Announces Presentation to Update on RAPTOR LNP Platform and CAR-M Therapeutic Programs
Read moreDeliver, but not to the liver: Liberate Bio developing targeted nucleic acid delivery technologies
Read more